A big Novartis deal turns on a quirk of how drugs are paid for in the U.S.: Insurers have less control over drugs given in hospitals than pharmacies
Novartis AG Chief Executive Vas Narasimhan has spent the past two years buying up cutting-edge science. His latest deal is a high-stakes bet that the Swiss health-care giant will succeed where many have struggled: launching a new heart drug.
Cardiovascular diseases are the number-one cause of death in the U.S., but new drugs for conditions like high cholesterol and heart failure have proven tough to sell. They compete with a bevy of older, cheaper drugs, and cardiologists typically want to see evidence that patients benefit...
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Turkey signs maritime boundaries deal with Libya amid exploration rowLibya's internationally recognized government and Turkey have signed an agr...
Baca lebih lajut »
Trump says the US-China trade deal is in its 'final throes' — but analysts are skeptical'I'm holding it up because it's got to be a good deal,' Trump later said to former Fox News host Bill O'Reilly.
Baca lebih lajut »
Exclusive: South Korea, Japan set to back air traffic deal after near missesSouth Korea and Japan are setting aside historical grievances to redraw responsi...
Baca lebih lajut »
Iran says it’s staying within the ‘general framework’ of the nuclear dealIn a recent statement to the International Atomic Energy Agency (IAEA), Iran has reiterated its commitment to the nuclear deal while Washington continues to sabotage the landmark agreement.
Baca lebih lajut »
EU states reach deal to ease banks' bad loan recoveryEuropean Union governments reached a deal on Wednesday on new rules to facilitat...
Baca lebih lajut »